Greetings. And welcome to Proto Labs Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Jason Frankman, Vice President and Corporate Controller. Thank you. Please go ahead.

Thank you, Donna. And welcome, everyone, to Proto Labs second quarter 2022 earnings conference call. I'm joined today by Rob Bodor, Proto Labs' President and Chief Executive Officer, and Dan Schumacher, Chief Financial Officer. This morning, Proto Labs issued a press release announcing its financial results for the second quarter ended June 30, 2022. The release is available on the company's website. In addition, our prepared slide presentation is available online at the web address provided in our press release. Our discussion today will include statements relating to future performance and expectations that are or may be considered forward-looking statements and subject to many risks and uncertainties that could cause actual results to differ materially from expectations. Please refer to our earnings press release and recent SEC filings, including our annual report on Form 10-K for information on certain risks that could cause actual outcomes to differ materially and adversely from any forward-looking statements made today. The results and guidance we will discuss include non-GAAP financial measures consistent with our past practice. Please refer to our press release and the accompanying slide presentation at the Investor Relations section of our company website for a complete reconciliation of GAAP to non-GAAP results. Now, I'll turn the call over to Rob Bodor. Rob?

Thanks, Jason. Good morning, everyone, and thank you for joining our second quarter earnings call. I'm happy to report another strong quarter with revenue and EPS within or above our guidance ranges. Despite ongoing supply chain challenges in the broader manufacturing industry and macroeconomic growth concerns, Proto Labs comprehensive digital manufacturing offer continues to delight our customers. Highlights of our second quarter performance includes strong growth in our CNC machining, 3D printing, and sheet metal services, as well as another quarter of strong growth at Hubs. Both the Proto Labs and Hubs offers continue to resonate in the marketplace, and we are now more excited than ever to bring the two offers together by the end of this year. In addition, pricing optimization and cost controls drove sequential improvements in both gross and operating margins. While we are very pleased with the performance in our CNC machining, 3D printing, and sheet metal services, revenue in our injection molding service did not meet our expectations in the second quarter. As was the case in the first quarter, our injection molding growth rate was negatively impacted by the absence of several large COVID-related medical orders that occurred in the first half of 2021. In addition, we experienced many customers placing unusually large orders in 2021 in order to stockpile inventory during that time of high uncertainty. In 2022, that behavior has significantly reduced among our customers, in line with macro inventory trends in the industries we serve. Furthermore, the unprecedented surge of orders in 2021 led to record high backlogs for us. These extended lead times, coupled with system inefficiencies we described in prior quarters, impacted our customers. We have addressed this operationally, and our fastest lead times are fully available today. We're focusing on go-to-market teams, on targeted campaigns to inform…

Thanks, Rob. And good morning, everyone. We are pleased with our financial results in the quarter, including record quarterly revenue and non-GAAP earnings per share above our guidance range. Before I walk through our financial results in detail, I'd like to highlight the financial rationale behind our decision to exit Japan. After 13 years of operation, Japan represented 3% of our total revenue in 2021 or $13 million. In the same amount of time, our Americas and Europe business had grown to over five times that size. In addition, between 2009 and 2021, Pro Labs Japan achieved profitability in only four of those years. Based on this, we determined that we could achieve higher potential returns by investing additional capital, time and resources in other areas of the business. Now, on to the numbers. Our second quarter financial results begin on page 7 of the presentation. Second quarter revenue of $126.9 million was within our guidance range and represents a 3.1% increase year-over-year or 5.4% in constant currencies. Hubs generated $11.3 million of revenue in the second quarter, representing growth of 26.3% year-over-year. With the strengthening of the US dollar throughout the second quarter, we experienced a $2.7 million unfavorable impact to revenue in the quarter, slightly above our guidance of $2.5 million. Second quarter revenue by region is summarized on slide 11. In the Americas, our largest region, second quarter revenue grew 5.6% year-over-year. In Europe, second quarter revenue grew 3.9% year-over-year in constant currencies. Transitioning to revenue by service. Our CNC and 3D printing services continued their strong performance year-to-date with second quarter revenue growth of 17.7% and 12.6% year-over-year in constant currencies, respectively. Sheet metal revenue growth was also strong at 9.4% year-over-year. As Rob noted, our injection molding business has underperformed expectations in the first half…

[Operator instructions]. The first question is coming from Brian Drab of William Blair.

On injection molding, so it's declined in some quarters. The sequential decline is basically flat, but it's declined sequentially for the last four quarters. So, is there any specific reason that you can point to or can you give us some confidence that that business specifically is going to turn around in the second half? Just trying to figure out how to model this business now at this point.

When you look at it year-over-year, right, a year ago, we had a number of COVID-related orders that didn't recur. But as you look more broadly, during that period, we saw an unprecedented surge of orders across many customers and across many industries, right, as companies were stocking reserve inventory to weather the supply chain disruptions at the time. And so, in addition to that, the impact of that for our business specifically was –that surge in orders was coming at a time when there was difficulty in direct labor headcount. There was a shortage of direct labor headcount. And the timing was such that we had recently launched our new systems, and we had some inefficiencies due to those systems, right, that we've talked about. And so, all of those together impacted our on-time and led to record backlogs for us that took several quarters to resolve. Since then, we have made significant improvements operationally across all of that. We introduced automation in the factory, which improved our operational efficiency and also reduced our need for the same kind of level of direct labor as we scale revenue, and we improved – made improvements to our systems and made those more efficient. So, today, we stand totally ready to take all orders. We can offer all our world-class lead times. We can make molds in a day. And so, we're much better-positioned actually to deal with that level of demand today than we were a year ago. So, we're working right now to reengage those customers that were impacted, and our go-to-market teams are in the process of doing that to help us continue to drive demand.

Thanks for reviewing the year-over-year dynamics. So, you do feel like this is a business that, given those actions that you just mentioned that this is going to increase sequentially going forward? There's more uncertainty now just because of the macro environment as well, I guess. Can you make any statement on whether you see this injection molding business generating more revenue in the second half of 2022 than it did in the first half? Because it's just hard for me to model – I understand the year-over-year dynamics, but the last three quarters have been $53 million to $54 million in that range. Without any increased confidence, I don't know why – and the macro where it is, I don't know why I would forecast anything above $53 million or $54 million for injection molding.

Brian, we're still feeling pressures from a macro perspective. When we talk to economists, they're talking about increased inventories at our customers, resulting in less demand from our perspective. So, we are working to improve, from a go-to-market perspective, to continue to bring customers into our injection molding service offer, but it's uncertain right now with the macro headwinds.

And in that business, can you just drill down a little bit, it sounds like the challenge is more in the new molds business rather than the parts business? Or is it also parts just because production at some of these bigger orders that you were talking about were production and parts business?

Yes. Well, a lot of what we were seeing was in parts because we saw really strong surge in production parts business, and that's what we're seeing not recur. As Dan talks about, there's evidence that companies are sitting on high inventories. So, that's really where we expect some headwind.

Just the last question for me is just, can you remind me what impact this dynamic – the more challenged injection molding business has on overall company gross margin?

If we take a look at it, our injection molding gross margins have traditionally been around mid-50s. With the lower volume, our injection molding gross margins were around 50% in the quarter.

The next question is coming from Jim Ricchiuti of Needham & Company.

Just some follow-ups on the topic of injection molding. Curious, are you seeing any changes in the competitive dynamics in the market that might be contributing to some of the demand issues that you're seeing in this part of the business?

Obviously, we're known for speed and we offer the fastest lead times in the world in injection molding. In those lead times, we don't really run into competition. During the period that I described when we had the significant backlogs and our lead times were longer during that period, our customers could look at other alternatives. There are local molders. So I think that's the dynamic that we're now really focused on overcoming as we drive our go-to-market teams to reengage those customers.

Maybe just to talk about the overall level of demand, are you seeing in the market – just in light of all of the concerns people have about macro, how did the business track or trend as you went through the June quarter? What are you seeing thus far in Q3 and whether you want to deal with that by geographic region, the US versus Europe, or even talk about it in terms of changes you might be seeing in any of your major vertical markets?

Let me first say, on a constant currency basis, our services outside of injection molding grew 15% year-over-year. So we're very happy with what happened there. In terms of what we're seeing in markets, like what we talked about from an injection molding perspective where we had some larger COVID orders in the last year., so medical was on the lower – declined slightly year-over-year, and then automotive was a headwind. But we saw things really strong from the end markets of aerospace in both industrial and commercial machinery, both were strong. If you take a look at in our non-GAAP disclosures, you can see that we had growth – constant currency growth across all regions. So we were very pleased with that in the quarter.

And going into Q3, the final question, just any change in customer behavior, one way or the other, in some of the markets that – your larger markets?

Yes. We've gone through July. We really haven't seen much change right now in terms of end customer behavior.

[Operator instructions]. The next question is coming from Greg Palm of Craig-Hallum.

I wanted to follow-up on the last question from Jim. If I look sequentially from Q2 at the midpoint, you're guiding down, call it, a couple of million, basically offsets the impact from the exit from Japan. Usually, Q3 is up at least a couple of million, $2 million, $3 million. So you said you're not really seeing much of a change, but guidance suggests maybe a little bit softer activity. Can you just maybe tie that out? Am I missing something?

I think the question was if I'm seeing anything from any specific end market, I read that by industry. I'm not hearing something different by industry. We set our guidance the same way we've done always. We're taking a look at what has happened through July, and then taking into account what we're seeing from an upload trend, what we're seeing seasonality. And so that's how we built our guide. And obviously, with that, as you can see from our guidance, we're not seeing right now as strong as a sequential uplift Q2 to Q3, at least as we look through initial results. So that's where that stands. We're continuing, from a macro headwind perspective, to look at injection molding. And understand what's happening there in terms of customers with the amount of inventory that they have on hand today and what that demand is. Some might signal there that with that trend, we would see a bigger upward trend in injection molding if the macro market was different.

As it relates to the Japan exit, I think you said over that time span only profitable four years. Can you say whether it was profitable in 2021, or was it profitable in recent quarters, at least on a full run rate basis?

It was not profitable in 2021, and it was not profitable this quarter.

And did you say the exit is going to have a negative impact on gross margins. Can you disclose what gross margins were in that region?

What I said, it's going to have a negative impact on gross margins in the next quarter. The reason it's having a negative impact on gross margins the next quarter is we have the equipment, we have the depreciation, we have a staff that's on production, and we're slowly shipping out the final orders. We expect to have that completed at the end of August or early September. And that's what's creating an unusually negative gross margin for Japan. It's not large enough to be a discontinued ops, so we can't completely remove it from our reporting from that perspective. And that's why, in that quarter, it has a negative impact. From a P&L perspective, the biggest challenge, and I talked about this, is that Japan was only getting to a $13 million revenue amount. And with the amount of sales and marketing and kind of infrastructure that you need overall, that was Japan's challenge to get to profitability.

At this time, I'd like to turn the floor back over to Mr. Bodor for closing comments.

Thank you for joining us on our second quarter earnings call. We're pleased with our performance in the first half of 2022, particularly in expanding our earnings. We have clear priorities in place and are focused on the execution of our strategy, which will lead to the long-term profitable growth. Thank you to our customers and shareholders for their continued support and to our employees for their continued efforts. We look forward to updating you on our performance next quarter. Have a great day.

Ladies and gentlemen, thank you for your participation and interest in Proto Labs. You may disconnect or log off the webcast at this time and enjoy the rest of your day.